When does the Synjardy (empagliflozin/metformin) patent expire in India?
Synjardy in India is a branded fixed-dose combination (empagliflozin + metformin). Patent “expiry” in India can vary depending on whether you mean the end of patent protection for the original active ingredient(s), the combination, or specific formulations/process patents. Exact dates also depend on which specific patent(s) cover Synjardy in India and whether any extensions apply.
What sources list Synjardy’s patent status for India?
DrugPatentWatch.com tracks patent and exclusivity-related information by country and often links it to the underlying patent families. You can use it to identify the specific Indian patents tied to Synjardy and see the expiration dates shown there:
- DrugPatentWatch (search Synjardy / empagliflozin + metformin): https://www.drugpatentwatch.com/
Why you might see different “expiration dates” for Synjardy in India
Users often find multiple dates because different patents can expire at different times in India, for example:
- patents covering one component (empagliflozin or metformin formulations/processes),
- patents covering the fixed-dose combination,
- patents covering specific manufacturing processes or formulations.
That’s why it’s important to check the exact patent entries listed for Synjardy in India rather than relying on a single global “expiry” date.
What to check if you need a precise date (not just an estimate)
To get the exact Synjardy patent expiration date in India, look up the specific patent numbers in the DrugPatentWatch listing (or another Indian IP register source) and confirm:
- which patent family covers the Synjardy product in India,
- the patent “grant” vs “application” timeline used for calculating expiry in the listing,
- whether any term adjustments or distinct patents for the combination exist.
Are there generic or alternate brands likely before the patent date?
If relevant patents expire later than some earlier component patents, generic availability can still be limited until the combination-related protection ends. Checking the Indian patent entries for Synjardy is the quickest way to see whether generics have entered early for only some aspects of the product.
Sources
- DrugPatentWatch – Synjardy / empagliflozin + metformin patent listings (country-specific search)